Free Trial

Acasti Pharma (ACST) Competitors

$2.84
-0.11 (-3.73%)
(As of 07/19/2024 08:55 PM ET)

ACST vs. ADAG, DERM, RGLS, PYRGF, CYTT, CTMX, INCR, FGEN, ORMP, and CRVO

Should you be buying Acasti Pharma stock or one of its competitors? The main competitors of Acasti Pharma include Adagene (ADAG), Journey Medical (DERM), Regulus Therapeutics (RGLS), PyroGenesis Canada (PYRGF), Cyteir Therapeutics (CYTT), CytomX Therapeutics (CTMX), InterCure (INCR), FibroGen (FGEN), Oramed Pharmaceuticals (ORMP), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry.

Acasti Pharma vs.

Adagene (NASDAQ:ADAG) and Acasti Pharma (NASDAQ:ACST) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.

9.5% of Adagene shares are owned by institutional investors. Comparatively, 6.1% of Acasti Pharma shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 13.5% of Acasti Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Adagene currently has a consensus price target of $5.00, suggesting a potential upside of 99.20%. Acasti Pharma has a consensus price target of $6.00, suggesting a potential upside of 111.27%. Given Adagene's higher probable upside, analysts clearly believe Acasti Pharma is more favorable than Adagene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adagene
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Acasti Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Adagene had 1 more articles in the media than Acasti Pharma. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Acasti Pharma. Acasti Pharma's average media sentiment score of 0.00 equaled Adagene'saverage media sentiment score.

Company Overall Sentiment
Adagene Neutral
Acasti Pharma Neutral

Acasti Pharma has lower revenue, but higher earnings than Adagene.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adagene$18.11M6.12-$18.95MN/AN/A
Acasti PharmaN/AN/A-$12.85M-$1.44-1.97

Adagene has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Acasti Pharma has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Acasti Pharma's return on equity of 0.00% beat Adagene's return on equity.

Company Net Margins Return on Equity Return on Assets
AdageneN/A N/A N/A
Acasti Pharma N/A -13.24%-11.33%

Acasti Pharma received 292 more outperform votes than Adagene when rated by MarketBeat users. However, 79.17% of users gave Adagene an outperform vote while only 70.52% of users gave Acasti Pharma an outperform vote.

CompanyUnderperformOutperform
AdageneOutperform Votes
19
79.17%
Underperform Votes
5
20.83%
Acasti PharmaOutperform Votes
311
70.52%
Underperform Votes
130
29.48%

Summary

Adagene beats Acasti Pharma on 7 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACST vs. The Competition

MetricAcasti PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$26.70M$6.76B$4.91B$8.32B
Dividend YieldN/A2.85%5.25%3.96%
P/E Ratio-1.9717.92148.2918.11
Price / SalesN/A474.072,259.19108.75
Price / CashN/A32.1033.7233.62
Price / Book0.435.834.854.63
Net Income-$12.85M$141.99M$105.58M$213.97M
7 Day Performance-7.49%1.87%118.11%2.69%
1 Month Performance-13.94%9.78%129.69%8.59%
1 Year Performance11.80%-2.71%132.09%3.64%

Acasti Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADAG
Adagene
1.1118 of 5 stars
1.11 / 5 stars
$2.57
-1.5%
$5.00
+94.6%
+83.2%$113.49M$18.11M0.00174Gap Down
DERM
Journey Medical
2.4238 of 5 stars
2.42 / 5 stars
$5.51
-3.8%
$9.75
+77.0%
N/A$110.26M$79.18M-17.7741
RGLS
Regulus Therapeutics
1.3865 of 5 stars
1.39 / 5 stars
$1.68
-1.2%
$11.75
+599.4%
+21.3%$109.99MN/A-1.1530News Coverage
PYRGF
PyroGenesis Canada
0 of 5 stars
0.00 / 5 stars
$0.61
-7.6%
N/AN/A$109.30M$9.14M-5.55120
CYTT
Cyteir Therapeutics
0 of 5 stars
0.00 / 5 stars
$3.01
-0.3%
N/AN/A$108.36MN/A-3.2046High Trading Volume
CTMX
CytomX Therapeutics
4.6202 of 5 stars
4.62 / 5 stars
$1.36
-5.6%
$5.77
+324.4%
-22.9%$105.97M$101.21M6.80170Positive News
INCR
InterCure
0 of 5 stars
0.00 / 5 stars
$2.28
-6.6%
N/A+39.4%$103.90M$96.61M17.54370Positive News
Gap Up
FGEN
FibroGen
4.4012 of 5 stars
4.40 / 5 stars
$1.04
-2.8%
$2.00
+92.3%
-50.0%$103.45M$167.49M-0.42486News Coverage
ORMP
Oramed Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
$2.52
-1.9%
N/A-19.6%$102.39M$1.34M9.6912Positive News
CRVO
CervoMed
0.8262 of 5 stars
0.83 / 5 stars
$16.58
-10.1%
$59.33
+257.9%
N/A$102.30M$7.14M0.008News Coverage

Related Companies and Tools

This page (NASDAQ:ACST) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners